SCHEMBL279616

SCHEMBL279616

Cc1ccc(C(=O)CN2CCCCC2)s1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
MAOB P27338 1/20 0.48
ALDH1A1 P00352 7/20 0.47
ACHE P22303 1/20 0.46
HPGD P15428 3/20 0.46
DAO P14920 1/20 0.46
MAPT P10636 2/20 0.44
ALPL P05186 1/20 0.44
ALPG P10696 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALOX15 P16050 1/20 0.44
HTR1A P08908 1/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 2/20 0.42
GLA P06280 1/20 0.42
MEN1 O00255 1/20 0.42
USP14 P54578 1/20 0.42
USP7 Q93009 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279637 0.86 ALDH1A1 (0.49) RAB9ANPC1ALDH1A1HPGDDAO
SCHEMBL279970 0.84 DAO (0.43) RAB9ANPC1ALDH1A1ACHEHPGD
SCHEMBL279862 0.84 ALDH1A1 (0.51) RAB9AALDH1A1HPGDDAOMAPT
SCHEMBL279617 0.83 DAO (0.42) RAB9ANPC1ALDH1A1HPGDDAO
SCHEMBL279992 0.79 DAO (0.44) RAB9ANPC1ALDH1A1HPGDDAO
SCHEMBL279886 0.77 ALDH1A1 (0.42) RAB9ANPC1ALDH1A1HPGDDAO
SCHEMBL280132 0.76 SMN1; SMN2 (0.46) RAB9ANPC1ALDH1A1HPGDDAO
SCHEMBL12124293 0.75 NPSR1 (0.57) RAB9ANPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL14174955 0.74 RAB9A (0.55) RAB9AACHE
SCHEMBL279975 0.73 NPSR1 (0.58) RAB9ANPC1ALDH1A1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL RAB9A 2458/4885NPC1 3107/4885MAOB 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.